VidaMed goes public
This article was originally published in Clinica
VidaMed, a developer of systems for the treatment of benign prostatic hyperplasia (BPH), went public with the sale of 3.1 million shares on June 21st. At a launch price of $6.50, a third below the price range mentioned in the prospectus, this was expected to raise in excess of $18 million net.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.